Top Story

FDA grants orphan drug status to ovarian cancer treatment

January 26, 2015

The FDA granted orphan drug designation to liposomal encapsulated paclitaxel, or LEP-ETU, an ovarian cancer treatment in development by Insys Therapeutics Inc., the company announced today.

“We are pleased to have received orphan drug designation for LEP-ETU to treat ovarian cancer, a devastating and difficult-to-treat disease,” Michael L. Babich, president and CEO of Insys Therapeutics, said in a press release. “By entrapping the paclitaxel with liposomes, we believe our LEP-ETU formulation could potentially have reduced toxicity, while maintaining or enhancing efficacy of the cancer-fighting paclitaxel. We are currently evaluating next steps with respect to this drug product candidate.”

In the Journals

Prognostic POLE proofreading may reduce overtreatment of endometrial cancer

January 14, 2015
POLE proofreading mutations may be independently prognostic for endometrial cancer and could help reduce overtreatment, according to data from a European…
In the Journals

Olaparib plus chemotherapy extended PFS in recurrent platinum-sensitive ovarian cancer

January 9, 2015
The addition of olaparib to paclitaxel and carboplatin followed by maintenance therapy with olaparib significantly extended PFS compared with chemotherapy alone in women…
Warner K. Huh, MD In the Journals

HPV testing recommended as primary screening option for cervical cancer

January 8, 2015
The HPV test should be considered the primary option for cervical cancer screening, according to an interim guidance report released today by two medical…
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
FDA approvals

FDA grants orphan drug status to ovarian cancer treatment

January 26, 2015
The FDA granted orphan drug designation to liposomal encapsulated paclitaxel, or LEP-ETU, an ovarian cancer treatment in development by Insys…
In the Journals

Prognostic POLE proofreading may reduce overtreatment of endometrial cancer

January 14, 2015
POLE proofreading mutations may be independently prognostic for endometrial cancer and could help reduce overtreatment, according to data from a…
In the Journals

Olaparib plus chemotherapy extended PFS in recurrent platinum-sensitive ovarian cancer

January 9, 2015
The addition of olaparib to paclitaxel and carboplatin followed by maintenance therapy with olaparib significantly extended PFS compared with…
Warner K. Huh, MD In the Journals

HPV testing recommended as primary screening option for cervical cancer

January 8, 2015
The HPV test should be considered the primary option for cervical cancer screening, according to an interim guidance report released today by two…
Gynecologic cancer group selects chair Institution Notes

Gynecologic cancer group selects chair

January 2, 2015
William Small Jr., MD, FACRO, FACR, FASTRO, has been named chair of the Gynecological Cancer Intergroup, an international organization of more than…
In the Journals

Women with BRCA-associated ovarian cancer have low risk for subsequent breast cancer

December 23, 2014
Women with epithelial ovarian cancer who harbor BRCA mutations appear to be at low risk for developing breast cancer, according to results of a…
In the Journals

Nitrogenous bisphosphonate use may reduce risk for endometrial cancer

December 22, 2014
Exposure to nitrogenous bisphosphonates appeared to have a protective effect on the incidence of endometrial cancer in women who never had the…
Richard Pazdur, MD FDA approvals

FDA approves Lynparza, companion diagnostic for advanced ovarian cancer

December 19, 2014
The FDA today approved olaparib for heavily pretreated women with advanced ovarian cancer associated with BRCA mutations.The approval also included…
Karen Midthun, MD FDA approvals

FDA approves 9-valent HPV vaccine for certain cancers

December 10, 2014
The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of…

Increased hospital-based services for ovarian cancer highlight need for end-of-life plans

December 4, 2014
Although the receipt of hospice care has increased over time among older patients with ovarian cancer, the rates for ICU admissions, hospitalizations…
More Headlines »
morganatic-roan
morganatic-roan